Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Eli Lilly

Novo Nordisk's shares have benefited from some recent positive developments. The delay in the approval of donanemab has held back Eli Lilly's valuation.

Will Novo Nordisk Overtake Eli Lilly as the Most Valuable Healthcare Stock?

Eli Lilly's Mounjaro and Novo Nordisk's Ozempic and Wegovy are headliners in the expected boom in GLP-1 weight-loss drugs. But investors are making even more money on tangential players.

Feisty Rivals Take On Eli Lilly, Novo Nordisk On Weight Loss

Weightwatchers International Inc.

A new medical study is raising concerns over whether intermittent fasting, a weight-loss method that's gained attention in recent years, could pose heart-health risks.

A new study cites the health risks of intermittent fasting. Could it lift Ozempic sales?

Novo Nordisk is enjoying stunning growth thanks to its breakthroughs in diabetes and obesity. The company is looking to augment its obesity care line with an oral drug called amycretin.

Is Novo Nordisk on the Verge of Another Blockbuster Drug?

Novo Nordisk and Eli Lilly have witnessed staggering success with their diabetes and obesity treatments. Both companies have been testing the main compounds in their respective medications for additional indications -- particularly in heart disease.

Did Novo Nordisk Just Get a Jump on Eli Lilly?

Madrigal Pharmaceuticals

Last week's FDA approval of Rezdiffra in treating NASH is a huge milestone for Madrigal. Lilly and Novo Nordisk look much more impressive than Madrigal in most ways.

Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?

The Novo Nordisk Foundation chooses Eviden to build “Gefion” in Denmark, one of the world's most powerful AI supercomputers

Novo Nordisk (NVO) concluded the recent trading session at $132.89, signifying a +0.39% move from its prior day's close.

Novo Nordisk (NVO) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Roche Holding AG

Novo Nordisk's Wegovy represents a significant advancement in obesity treatment, demonstrating a more profound weight-loss effect compared to its predecessor, Saxenda. Eli Lilly's entry with Zepbound, targeting both GLP-1 and GIP, signifies a competitive market landscape, potentially outperforming Wegovy in efficacy. The race to redefine obesity treatment is heating up, with several other pharmaceutical companies developing GLP-1 agonists and exploring alternative targets.

Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront

The Novo Nordisk Foundation, top shareholder of Danish obesity drugmaker Novo Nordisk , plans to give a larger portion of its social, scientific and humanitarian grants outside of Denmark, a foundation spokesperson said on Monday.

Novo Nordisk foundation to place more grants outside Denmark

Some health plans and employers are still reluctant to cover Wegovy due to its hefty price tag, which they say could significantly strain their budgets.

Weight loss drug Wegovy is now approved for heart health — but that won't mean broad insurance coverage just yet

Novo Nordisk is a leader and innovator in the diabetes drug market. The pharmaceutical company is making strides in obesity care, too.

Novo Nordisk Isn't in The "Magnificent Seven," but Here's Why I Think It Should Be

Novo Nordisk recently presented encouraging phase 1 results for an oral obesity treatment candidate. The company has many more promising programs in its early-stage pipeline.

Novo Nordisk Is Already Working on Wegovy's Successor -- Time to Buy?

Vertex Pharmaceuticals

Investors need not be concerned about the FDA's approval delay for Eli Lilly's Alzheimer's drug. Novo Nordisk recently picked up a regulatory win that makes the stock even more attractive.

3 Unstoppable Stocks You Can Buy Now Without Any Hesitation

Weight loss drug Wegovy is now approved for heart health - but that won't mean broad insurance coverage just yet

Advanced Micro Devices

Amazon

ASML Hld

AstraZeneca

NVIDIA

Toyota Motor

By definition, mega-cap stocks are those which possess a market capitalization above $200 billion. So, investors seeking to turn $10,000 into $1 million through Mega cap companies will be choosing from the top 60 companies on this list.

7 Mega-Cap Stocks That Can Turn $10,000 Into $1 Million

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Novo Nordisk (NVO) is a Top Momentum Stock for the Long-Term

Novo Nordisk primarily focuses on the diabetes and obesity markets with medications like Ozempic and Wegovy. Wegovy was recently granted an extended indication from the FDA to treat cardiovascular disease.

Novo Nordisk Just Scored a Huge Win. And It's Not Related to Ozempic

Global X Health & Wellness Thematic ETF

When many investors hear the word mania, they may think of artificial intelligence (AI) stocks or Bitcoin. Both investments have yielded market-beating returns and have room to run higher.

3 Weight-Loss Stocks to Buy as GLP-1 Mania Takes Hold

Broadcom

Taiwan Semiconductor Manufacturing

Visa

Tesla has fallen behind six other companies in terms of market cap. These alternatives dominate industries, including weight management, payments, and semiconductors.

Move Over, Tesla! These 6 Stocks Could Replace It in the "Magnificent 7"

Hims & Hers Health

LifeMD 

Teladoc

WW International Inc. NASDAQ: WW (WeightWatchers) has had a disastrous 2024, with its shares collapsing 66.7% year-to-date (YTD). The company made a praiseworthy strategic pivot in 2023, acquiring Sequence Inc. to enter into the GLP-1 clinical weight loss space, gaining the ability to prescribe medications like Novo Nordisk A/V NYSE: NVO owned Ozempic and Wegovy and Eli Lilly& Co. NYSE: LLY GLP-1 agonists like Mounjaro and Zepbound.

Can WeightWatchers Regain Its Mojo after Oprah Steps Down?

A research firm added the European pharmaceutical sector star to its focus list. It was among four stocks earning this status.

Why Novo Nordisk Stock Was a Winner Today

Does Novo Nordisk (NVO) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Novo Nordisk (NVO) a Strong Momentum Stock: Buy Now?

Novo Nordisk (NVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Novo Nordisk (NVO) Rating Upgrade to Buy

Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk , plans to open an office in India this year to tap innovation and a growing healthcare market, its CEO Kasim Kutay said on Tuesday.

Novo Nordisk-owner to expand in India this year

News for Novo Nordisk Stock (NVO)